Notably, the majority of these mutations (56, representing 39.4%) was identified in the BRCA1/BRCA2 genes, primarily associated with breast (26.7%) and ovarian cancer (8.4%) syndromes. Here, BRCA2 is linked to ovarian carcinoma.